Catalyst Funds Management Pty Ltd Grows Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Catalyst Funds Management Pty Ltd increased its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 2,083.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,100 shares of the biotechnology company’s stock after purchasing an additional 12,500 shares during the period. Catalyst Funds Management Pty Ltd’s holdings in Aldeyra Therapeutics were worth $65,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ALDX. State Street Corp boosted its position in Aldeyra Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after buying an additional 16,188 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after buying an additional 295,864 shares during the period. Barclays PLC boosted its position in Aldeyra Therapeutics by 280.1% in the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 48,313 shares during the period. SG Americas Securities LLC boosted its position in Aldeyra Therapeutics by 14.4% in the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 2,822 shares during the period. Finally, AlphaCentric Advisors LLC purchased a new stake in Aldeyra Therapeutics in the 4th quarter valued at about $234,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Trading Up 1.5 %

NASDAQ:ALDX opened at $6.91 on Monday. Aldeyra Therapeutics, Inc has a one year low of $2.71 and a one year high of $7.20. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The firm has a 50-day simple moving average of $5.79 and a 200-day simple moving average of $5.47.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.30). On average, equities research analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Monday, March 3rd.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.